Infectious-disease prevention and treatment

Source date: 2026-11-10. Recorded in this review: November 10, 2026.

Evidence: Sponsor-only long-term antibody follow-up; historical FDA safety and access context.

Valneva reports 94% seroresponse among 221 evaluable healthy adults at year five after one IXCHIQ dose (VLA1553-303), with broadly similar older/younger adult persistence. This is a neutralizing-antibody surrogate in retained participants, not 94% clinical efficacy or a randomized five-year safety comparison; full attrition, confidence intervals and new quantitative harms are absent. Ten-year follow-up is planned without a firm next public result date.

U.S. context: FDA lists manufacture discontinued January 2026 and a requested voluntary license revocation; Purple Book currently says Disc/Revoked.

The August 22, 2025 license suspension followed serious chikungunya-like illness, hospitalizations and vaccine-strain encephalitis; clinical benefit had not been confirmed. These are historical facts recovered as context, not new November safety actions. Do not describe the live vaccine as currently U.S.-available or convert Brazil campaign reach into demonstrated effectiveness.

Next milestones: IXCHIQ longer-term antibody and clinical-effectiveness data: date unknown (Protocol follow-up; public date unknown).

Sources: GlobeNewswire · news release; valneva.com · news release; FDA · regulatory information; FDA · regulatory information; FDA · regulatory document.

Source date: 2026-11-09. Recorded in this review: November 10, 2026.

Evidence: Sponsor-only Phase 2 topline; effect magnitude undisclosed.

Valneva/LimmaTech report that S4V03 met its primary S. sonnei 53G challenge endpoint after two vaccine or placebo doses one month apart. The release says approximately 120 adults; completed NCT06615375 records 97 actual participants. Do not present 120 as randomized or challenged. Exact challenge-arm counts, attack rates, effect size, confidence interval and numerical harms are absent.

Separate S4V02/NCT06523231 enrolled 110 nine-month-old Kenyan infants, comparing two dose levels with MenACWY. Reported anti-LPS IgG increases across four serotypes and persistence six months after dose two are immune responses, not observed infant protection. One adult challenge serotype does not establish field protection against all four.

Sponsor describes adverse events as mostly mild/moderate and treatment-related events as resolved, without complete rates. Investigational; Fast Track is not approval. Full data, dose optimization and next-stage plans remain undated.

Next milestones: Full S4V2 Phase 2 numerical results and future trial plan: date unknown (Unknown; sponsor evaluating next development steps).

Sources: GlobeNewswire · news release; valneva.com · PDF document; ClinicalTrials.gov · NCT06615375; ClinicalTrials.gov · NCT06523231.

Source date: 2026-11-08. Recorded in this review: November 10, 2026.

Evidence: Sponsor-only randomized open-label Phase 3 topline and conference report.

ECLIPSE 1/NCT06903338 randomized 124 adults 2:1 to monthly elebsiran plus tobevibart or 12-week delayed treatment. The prespecified comparison is ACTIVE WEEK 48 (n=83) versus DELAYED WEEK 12 (n=41), confirmed in the registry; this is not a 48-week untreated comparison. HDV RNA target-not-detected plus ALT normalization: 44% versus 0%, p<.0001; TND alone 79% versus 0%.

These are viral/laboratory endpoints, not demonstrated reductions in liver cancer, decompensation, mortality or proof of cure. No confidence intervals or full harms table.

One Grade 3 related neutrophil decrease resolved in 15 days; no treatment interruptions/discontinuations reported. Flu-like symptoms commonly followed the first dose.

Investigational; mid-2027 FDA filing is a sponsor forecast, not acceptance or approval. Primary completion September 30 was actual; longer follow-up continues. Full tables, ECLIPSE 2/3 comparisons and durability remain needed.

Next milestones: Elebsiran plus tobevibart U.S. FDA submission: 2027-mid (Sponsor forecast November 8; no FDA deadline).

Sources: investors.vir.bio · news release; ClinicalTrials.gov · NCT06903338.

Source date: 2026-11-08. Recorded in this review: November 10, 2026.

Evidence: Sponsor-only Phase 2 extension and exploratory nonrandomized withdrawal snapshot.

SOLSTICE/NCT05461170 reports 28/28 week-96 combination-treatment completers with HDV RNA TND, not all 95 enrolled patients. Improved or stable liver stiffness in 24/27 is a noninvasive measurement, not demonstrated histologic reversal or clinical benefit.

Ten eligible patients with ≥96 weeks of undetectable virus chose to stop treatment: ten achieved SVR12, seven SVR24 and one SVR48 at available follow-up, without observed rebound/ALT flare. Do not label all ten SVR48 or cured.

The company explicitly states there was no formal data cut, this is a selected interim snapshot, follow-up is incomplete, delayed hepatic flares are not fully assessed, and data may change.

The extended report describes no drug-related serious events/discontinuations and mild/moderate events, without full rates. Investigational; not routine permission to stop antivirals. Planned U.S. filing mid-2027 relies on the broader ECLIPSE package. Longer withdrawal follow-up/full tables have no verified date.

Next milestones: SOLSTICE longer post-treatment viral and ALT follow-up: date unknown (Unknown; exploratory follow-up ongoing).

Sources: investors.vir.bio · news release; ClinicalTrials.gov · NCT05461170.

Source date: 2026-11-05. Recorded in this review: November 10, 2026.

Evidence: Sponsor-only Phase 1 interim biomarker and safety update.

Precision’s original release is NOVEMBER 5, not November 6: September 28 cutoff, 25 ELIMINATE-B/NCT06680232 patients and 59 administrations. Eleven of 12 baseline-pgRNA-evaluable patients became undetectable, including all six evaluable at 0.4 mg/kg. This is not 25/25 cured or complete eradication of every reservoir. Paired biopsies in only two patients at 0.4 mg/kg show approximately 1- and 1.5-log cccDNA reductions. HBsAg reductions in 24 evaluable patients are biomarkers, not demonstrated off-treatment viral control or prevention of cirrhosis/cancer.

Selected Phase 2 dose: 0.4 mg/kg.

Infusion reactions and transient ALT/AST elevations occurred; no dose-limiting toxicity reported. At 0.4 mg/kg, no serious events reported. Under the CURRENT infusion protocol, 15 administrations in eight patients produced no Grade ≥3 hypotension. One delayed ALT 306/AST 278 U/L rise after the third administration resolved without intervention. These observations do not establish long-term editing safety.

Phase 2 first dose Q1 2027 and initial data H2 2027 are sponsor forecasts; protocol still finalizing. No approval.

Next milestones: PBGENE-HBV ELIMINATE-B2 first dose: 2027-Q1 (Sponsor forecast November 5; actual dosing unverified); PBGENE-HBV ELIMINATE-B2 initial open-label data: 2027-H2 (Sponsor forecast November 5).

Sources: precisionbiosciences.gcs-web.com · source page; businesswire.com · news release; ClinicalTrials.gov · NCT06680232.

Source date: 2026-09-29. Recorded in this review: November 10, 2026.

Evidence: Recovered peer-reviewed Phase 1 full publication; healthy volunteers only.

September 29’s WCK 6777/NCT05645757 paper studies once-daily IV ertapenem plus zidebactam, standalone components and placebo for seven days: 54 enrolled, 52 treated; total combination doses 2/4/6 g (1+1, 2+2, 3+3 g).

No deaths, serious events or treatment discontinuations were reported. Across all arms, 41/52 had an adverse event and 35/52 a treatment-related event, mostly mild/moderate. One asymptomatic moderate QTcF increase in the 4-g combination cohort remained unresolved at final visit after loss to follow-up: absolute QTcF 425 ms, +47 ms from baseline.

Healthy-volunteer findings do not prove cure of resistant infections, fewer hospitalizations or long-term safety. This is an existing-class/enhancer combination, not a wholly new antibiotic class. Study occurred in 2023 and registry results existed in 2024; the later full paper is not a new November efficacy result. U.S. approval and next patient-efficacy readout are not established.

Next milestones: WCK6777 controlled infection-treatment results: date unknown (Unknown; patient efficacy study not verified).

Sources: journals.asm.org · article; ClinicalTrials.gov · NCT05645757.

Source date: 2026-09-26. Recorded in this review: November 10, 2026.

Evidence: Recovered peer-reviewed Phase 1b full publication; old completed trial, not November readout.

The September 26 full paper reports DSTA4637S, an anti-S. aureus antibody linked to a rifamycin, added to standard antibiotics in complicated MSSA/MRSA bacteremia (NCT03162250). The trial enrolled in 2017–2019: 27 randomized, 25 treated (19 active, six placebo); weekly 15/45/100 mg/kg for four to six doses.

Four of 19 active patients stopped for related infusion reactions. Grade ≥3 events in 18/25 and serious events in 14/25 are all-arm counts, not attributable drug-harm rates. One active-arm death was assessed unrelated; one patient developed rifampin-resistant S. aureus. Exposure was 30–60% lower than in healthy volunteers. Efficacy was not powered/tested; no cure advantage established. Earlier IDWeek 2020 presentation is disclosed.

The authors explicitly state that further development of DSTA4637S for S. aureus bacteremia is not planned because of safety and pharmacokinetic findings. No U.S. approval is established; do not assign an active next-trial forecast.

Sources: PubMed Central · PMC13643602; PubMed · PMID 42846794; DOI · 10.1093/ofid/ofag608; ClinicalTrials.gov · NCT03162250.

Coverage and remaining gaps: Reviewed the full saved topic corpus, scope and state. Retrieved all 260 ClinicalTrials.gov November 3–10 discovery records across three pages and all named records within 71 combined airway/infection IDs. Appraised primary Shigella, chikungunya, antibiotic and hepatitis B/delta sources; three HBV/HDV raw registries verified comparison windows and trial identities. Worldwide appraisal back to the September overlap remains incomplete. Complete worldwide literature, non-U.S. registries, regulator and safety census and original audio/Q&A are unfinished. Do not advance full successful-check dates. S4V2 exact challenge denominators, effect size and detailed harms remain unavailable. IXCHIQ five-year full attrition and clinical efficacy are not established. EMA phage workshop proceedings, GSK HSV vaccine detailed results and new rifaximin/azithromycin diarrhea tables remain unappraised. Flu/COVID combination NCT07890454 remained not yet recruiting after the November 9 estimate. HBV/HDV full conference talks, webcast recordings, complete harms and long-term clinical outcomes remain unappraised; unequal comparison windows and selected withdrawal denominators are preserved.

Informal-source coverage: Revisited the original RadicalNumerics blog and found an original Podovirus patient-advocate transcript. Later Omnii coverage traces to the same developer claim; no independently verified clinical course or authorization was recovered. Searches for the earlier adibelivir administrative and anonymous Mayo UTI phage leads did not verify a new formal event. Full audio and precise original comment links remain gaps.

Full coverage record.

Source date: 2026-11-05. Recorded in this review: November 6, 2026.

WHO's November 4 release recommends Oxford/Serum Institute ChAdOx1 and Moderna mRNA-1469 for addition to the Tumaini ring-vaccination trial in the DRC, conditional on national approvals. This is planned evaluation against Bundibugyo virus, not proven cross-protection or approval. WHO forecasts vaccine findings in early 2027 and treatment findings in coming months; it also plans to add maftivimab to the separate PARTNERS treatment trial. No new efficacy or safety estimates are supplied.

Separately, NCT07919197 first posted November 5 is an observer-blind, placebo-controlled Phase 1 mRNA-1469 safety/immunogenicity trial planning 224 participants aged 1–65 in Uganda. It is not the Tumaini efficacy cohort. The record remains not yet recruiting despite an elapsed November 2 start estimate; February 1, 2028 completion is also estimated. Antibodies/safety are distinct from prevented disease, and actual first dosing is unverified. No U.S. approval for this candidate is established.

Sources: who.int · news release; ClinicalTrials.gov · NCT07919197.

Source date: 2026-11-05. Recorded in this review: November 6, 2026.

Moderna's NCT07919210 plans 64 healthy adults aged 18–55 to receive mRNA-1519 or placebo under observer masking. It tests one injection or two injections on days 1/57 at three labeled dose levels; level 1 includes single-dose and two-dose regimens, while levels 2 and 3 use one injection; numerical amounts are not public in the appraised record. Primary endpoints are reactogenicity and adverse events, with Marburg antibody measures secondary. There are no prevented-infection or survival results.

Not yet recruiting at the Oxford site, despite an elapsed November 2 estimated start. April 14, 2028 completion is estimated, not a result-release commitment. No human efficacy, long-term safety or U.S. approval established.

Sources: ClinicalTrials.gov · NCT07919210.

Source date: 2026-11-06. Recorded in this review: November 6, 2026.

MOTIVATION (NCT07922226) lists planned enrollment of 6,600, with maternal eligibility ages 18–49 and follow-up of their infants, comparing GBS-NN/NN2 vaccine with saline placebo. The two maternal intramuscular injections are scheduled around gestational weeks 24 and 32; the formulation contains 50 micrograms of each fusion protein plus 500 micrograms aluminium. This combined Phase 2/3 trial emphasizes functional infant antibody titres and prespecified protective thresholds, together with maternal/infant serious and special-interest adverse events.

These endpoints should not be relabeled as directly observed reductions in newborn sepsis, meningitis or mortality. Not yet recruiting, with November 30, 2026 estimated start and May 22, 2030 primary/final completion. No human outcome results, comparative pregnancy safety or U.S. approval are established; completion is not promised publication.

Sources: ClinicalTrials.gov · NCT07922226.

Related findings, recorded once: Nasal mRNA therapy shows an early antiviral signal in asthma (GlobeNewswire · news release).

Coverage and remaining gaps: focused_incomplete; Broad query contains unrelated oncology/dental/other drug records. Novel-antibiotic manuscripts, all global registers and full phage workshop conclusions remain incompletely appraised. DSTA4637S paper and WCK6777 were surfaced as leads but not fully appraised; no efficacy claims added.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal-source coverage: Revisited Radical Numerics’ original October 20 developer blog and later source chain. The human-administration claim and undisclosed outcomes are already saved under omnii-phage-compassionate-administration; no new evidence or repeated alert. General phage discussions and laboratory AI-model results do not establish clinical benefit.

Full coverage record.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

RESOLVE (NCT07908381) plans 860 high-risk adult outpatients with confirmed RSV and symptom onset within 72 hours: age ≥75, or age ≥18 with COPD or congestive heart failure. It randomizes oral zelicapavir (EDP-938) 800 mg daily for seven days versus placebo, with masked treatment. The primary endpoint is time to complete resolution of 13 symptoms through day 21; hospitalization, death, viral load and adverse events are distinct secondary assessments through day 35. No new efficacy or safety results are posted.

The sponsor’s October 26 release announces first patient dosed, without specifying that day; the November 2 registry reports actual study start October 19 and recruiting. The Phase 2b portion targets at least 200, with approximately 660 in Phase 3; do not treat the entire planned enrollment as completed. Sponsor Phase 2b topline is forecast for 2027, while registry primary/final completion is July 2029. Zelicapavir remains investigational; prior subgroup signals are not confirmatory RESOLVE outcomes or U.S. approval.

Next milestones: RESOLVE Phase 2b topline: 2027 (Sponsor forecast; exact day unknown); RESOLVE primary completion: 2029-07 (Registry estimate; not promised readout).

Sources: ClinicalTrials.gov · NCT07908381; ir.enanta.com · news release.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

ARTISTRY-3 (NCT07908446) plans 400 virologically suppressed adults with HIV, randomized open-label to immediate daily bictegravir/lenacapavir 75/50 mg or continued stable therapy until switching at week 24. On the first two switch days, an additional oral lenacapavir 600 mg loading dose is given in addition to the daily 75/50 mg tablet. The primary endpoint is HIV RNA ≥50 copies/mL at week 24 for a noninferiority comparison; suppression, serious/grade 3–4 adverse events and treatment experience are separate outcomes.

This is a daily oral treatment regimen, distinct from twice-yearly injectable HIV prevention. Bixlenvo’s existing August 27, 2026 FDA approval is restricted to switching suppressed adults without known/suspected resistance to its components; the new registration is not another approval or a cure. It is not yet recruiting, with November 2026 estimated start, July 2028 primary and November 2028 final completion. No results posted.

Next milestones: ARTISTRY-3 estimated start: 2026-11 (Registry estimate; not yet recruiting); ARTISTRY-3 primary completion: 2028-07 (Registry estimate; publication unknown).

Sources: ClinicalTrials.gov · NCT07908446; FDA · approval letter; investors.gilead.com · news release.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

Unitaid/Wits RHI/CHAI and Dr. Reddy’s report FDA tentative approval of generic injectable lenacapavir, with an agreed US$40-per-person annual price in 120 low- and middle-income countries covered by Gilead’s license. Initial supplies are forecast by end-2026 and broader availability in 2027; actual deliveries and each country’s authorization remain separate. The original FDA tentative letter was not retrieved in this review, so this regulatory status is attributed to the partners.

Tentative approval does not authorize U.S. generic sales while patent/exclusivity restrictions remain. This is an access development rather than new efficacy evidence or a new U.S. PrEP indication. HIV testing before initiation and repeat dosing remains important because undetected infection can select resistance; injection reactions and delivery continuity remain relevant. Country introduction, procurement and health-system delivery determine actual access.

Next milestones: Initial generic lenacapavir country supplies: 2026-end (Partner forecast; actual delivery unverified).

Sources: wrhi.ac.za · news release.

Source date: 2026-11-03. Recorded in this review: November 3, 2026.

The new SER-155 paper (NCT04995653) includes an open-label cohort of 15 and a randomized cohort of 45 allogeneic hematopoietic-cell transplant recipients. The efficacy set includes only 34 who received study treatment and transplant: 20 active/14 placebo. The regimen combines oral vancomycin conditioning with a cultivated multi-strain live biotherapeutic; placebo covers both components.

Through transplant day 100, bloodstream infections occurred in 2/20 versus 6/14: OR 0.15 (95% CI 0.01–1.13), Fisher p=.0423. Retain the reported interval crossing 1 and p-value rather than reconstructing certainty. Other secondary clinical endpoints were not significant. Safety and strain engraftment were primary endpoints. The randomized-cohort safety set was 21 active/19 placebo, distinct from efficacy denominators. No treatment-related serious events or SER-155-species infections were reported; diarrhea/nausea were common. Four randomized-cohort deaths occurred, two per arm, and four in the open-label cohort; none was attributed to SER-155.

The small selected post-randomization set, imprecision and different vancomycin exposure limit causal/general-population inference. This full publication adds detail to older sponsor reports; it does not establish mortality benefit, replace antibiotics or confer U.S. approval. Confirmatory results have no verified date.

Next milestones: Confirmatory SER-155 clinical outcomes: date unknown (No dependable date verified).

Sources: Nature · article; ClinicalTrials.gov · NCT04995653.

Source date: 2026-10-30. Recorded in this review: November 3, 2026.

FDA granted accelerated approval to VOCERYQ (INO-3107; doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP). These usually benign HPV-6/11 airway lesions are distinct from cancer and primary-prevention HPV vaccination. This resolves the previously unverified October 30 action target.

The label uses four 6.25 mg intramuscular doses, three weeks apart, with CELLECTRA 5PSP electroporation, following surgical debulking. In open-label RRP-001/NCT04398433, 32 adults received treatment; the FDA efficacy subset was the 26 with at least three prior-year surgeries, including the pre-treatment excision. 7/26 (27%; 95% CI 12–48%) needed no surgical excision over the subsequent 12-month assessment. There was no randomized comparator; surgery-free response is not proof of cure or comparative superiority.

Safety uses all 32: injection-site reactions 11/32, headache 6/32, fatigue 5/32, hypertension 4/32, nausea and dizziness 2/32 each. Electroporation adds procedure-related risks; small-study tolerability does not establish uncommon or long-term safety.

Continued approval requires confirmation of clinical benefit. FDA requires a controlled study of at least 50 adult/pediatric participants, with at least three years' post-treatment assessment; the pediatric confirmatory plan does not broaden the current adult indication. Draft/final protocols are due December 30, 2026 / June 30, 2027, completion December 30, 2031, and final report August 30, 2032. The sponsor forecasts order/shipping availability in approximately 60 days and full launch in Q1 2027; immediate commercial access is not verified.

U.S. status: FDA accelerated approval for adult RRP surgical-burden reduction; confirmatory benefit remains required. Sponsor shipping/launch forecasts are separate from approval.

Next milestones: VOCERYQ confirmatory draft protocol due: 2026-12-30 (FDA postmarketing requirement); VOCERYQ confirmatory final protocol due: 2027-06-30 (FDA postmarketing requirement); VOCERYQ full commercial launch: 2027-Q1 (Sponsor forecast); VOCERYQ confirmatory study completion due: 2031-12-30 (FDA postmarketing requirement); VOCERYQ confirmatory final report due: 2032-08-30 (FDA postmarketing requirement).

Sources: FDA · announcement; FDA · regulatory information; FDA · regulatory information; ir.inovio.com · news release.

Coverage and remaining gaps: focused_incomplete. SER-155 is a small selected post-transplant efficacy set; further confirmatory evidence needed. Generic lenacapavir’s original FDA tentative letter and actual country deliveries were not retrieved. EMA phage workshop original report/conclusions remain unappraised. Antibiotic, vaccine, antiviral and international-registry coverage remains incomplete.

Informal-source coverage: AI-phage reporting continues to trace to the same compassionate-use sponsor claim without patient outcome disclosure; repeats are not independent confirmation. Informal search and original podcast/audio appraisal remain partial.

Full coverage record.

Source date: 2026-10-20. Recorded in this review: October 30, 2026.

The paper was first published October 20; the investigator’s October 28 notice is later publicity, not a new trial. In ADAPT-Sepsis, 2,760 critically ill adults across 41 UK units were assigned PCT guidance, CRP guidance or usual care. The process evaluation found first strong-stop advice 1.7 days earlier with PCT versus CRP (95% CI −2.5 to −0.9), while overall protocol adherence was 76.3% versus 83.1% (difference −6.8 percentage points, CI −9.0 to −4.5).

These are advice timing and implementation measures, not 1.7 fewer antibiotic days or a new mortality benefit. Stop-advice adherence was inferred from cessation of trial blood sampling, and descriptive reasons for nonadherence are not randomized causal comparisons. Clinical benefit and safety belong to the separately published main trial. This is stewardship alongside clinical assessment, not a new antibiotic, standalone sepsis diagnosis or U.S. product approval. No new outcome-readout date announced.

Sources: DOI · 10.1111/anae.70439; manchesterbrc.nihr.ac.uk · source page.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

NCT07902583 plans 36 healthy adults aged 18–55 in an open-label sequential, nonrandomized Phase 1 study of Cov-RBD-scNP-001 with or without ACU-026-001-1 adjuvant. It studies safety/reactogenicity and breadth of immune responses to betacoronaviruses. Safety endpoints include local/systemic reactions and longer follow-up for serious and immune-mediated events.

No human safety, immune-response or infection-prevention results are posted. Broader neutralization would not by itself establish broad clinical protection or durability. The study is not yet recruiting: November 16, 2026 start and October 7, 2027 completion are estimates. This is investigational, not a U.S.-approved universal coronavirus vaccine.

Next milestones: Pancoronavirus Phase 1 estimated start: 2026-11-16 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07902583.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

The original EMA page links an agenda updated October 29 for the October 30, 9 a.m.–6 p.m. CET workshop. At this check the scheduled window has ended, but original proceedings, conclusions or a final report were not appraised. The page offers a broadcast; passing the end time does not independently verify each presentation or enact new law. This regulatory discussion is separate from clinical efficacy, U.S. approval and standardized access. Retain an awaiting-report milestone rather than silently marking recommendations adopted.

Next milestones: EMA phage workshop proceedings/report: date unknown (Awaiting original report; no date verified).

Sources: EMA · source page.

Coverage and remaining gaps: focused_incomplete. Hibsago actual commercial access remains unverified. EMA original proceedings/conclusions and INO-3107 FDA action are unverified as of check; today’s target is not an approval. Full antibiotic/phage/antiviral appraisal remains incomplete.

Informal-source coverage: Previously recorded AI-phage discussion repeats the same sponsor compassionate-use announcement without patient outcomes. No independent clinical confirmation from reposts. Original podcast/talk coverage remains partial.

Full coverage record.

Source date: 2026-10-20. Recorded in this review: October 27, 2026.

Source/event date: FDA approval announced October 20; recovered in this October 27 review, not newly approved today.

Indication and evidence: Hibsago (bepirovirsen) is an antisense therapy for adults with chronic hepatitis B without cirrhosis, on nucleos(t)ide reverse-transcriptase inhibitor treatment for at least six months, with suppressed HBV DNA and HBsAg ≤3,000 IU/mL measured by an authorized test. The labeled course adds 24 weeks of injections to existing antiviral treatment; background antiviral therapy continues for at least another 24 weeks, and only selected patients meeting specified criteria may stop under monitoring. In the pooled B-Well 1/2 efficacy set, 233/1,220 (19%) versus 0/614 controls met the week-72 endpoint of sustained HBsAg loss and suppressed HBV DNA after 24 weeks off all HBV treatment. The 79% figure sometimes quoted is 233/295 selected patients who qualified to stop, not 79% of everyone treated. This is functional control, not proof that all viral reservoirs are eradicated or that cirrhosis, liver cancer or mortality are reduced.

Harms: The FDA label has boxed warnings for hepatic flares and thrombocytopenia, which can be life-threatening. Renal decline and immune-mediated reactions also require attention. Safety denominators are 1,223/611, distinct from efficacy denominators; adverse-event discontinuation was 3% versus <1%, and injection-site reactions 57% versus 15%.

U.S. status and next milestone: Approved for the restricted labeled population; actual commercial launch and coverage were not independently verified. The companion HBsAg assay authorization is distinct from clinical outcomes. See also liver health; this approval is recorded once here.

Sources: primary source; Hibsago FDA prescribing information; gsk.com · news release; ClinicalTrials.gov · NCT05630807; ClinicalTrials.gov · NCT05630820.

Source date: 2026-10-27. Recorded in this review: October 27, 2026.

Registry first posted October 27; sponsor announcement October 14: FLINTLOCK (NCT07899346) plans 130 adults aged 18–65 in a randomized masked placebo-controlled Phase 2a study. Long COVID and persistent post-vaccination symptoms are separate cohorts. The regimen is intravenous VYD2311 on day 1 followed by intramuscular dosing on days 30/60 and 90-day follow-up.

Outcomes and limits: Primary outcomes are safety and serum drug concentrations; symptom/function scales are secondary. Viral-spike persistence and the cause of post-vaccination symptoms are hypotheses, not established by cohort eligibility. There are no results or demonstrated cure. Sponsor wording that the trial was initiated does not verify first dosing: the October 27 registry is not yet recruiting with an estimated October 2026 start.

U.S. status and timing: VYD2311 is investigational; another product’s pre-exposure-prevention authorization does not approve this use. June 2027 estimated completion is separate from the sponsor’s mid-2027 initial-data forecast. Actual recruitment and first dosing remain to verify.

Sources: ClinicalTrials.gov · NCT07899346; invivyd.gcs-web.com · news release.

Source date: 2026-10-22. Recorded in this review: October 27, 2026.

First posted October 22: Sanofi’s NCT07890454 plans 6,000 adults aged ≥60, comparing combined high-dose inactivated influenza/protein COVID vaccine with separate high-dose influenza and EU-licensed NVX-C19 vaccination. Both blinded groups receive two injections; the combination group has a placebo second injection.

Primary day-28 outcomes are influenza hemagglutination-inhibition and SARS-CoV-2 neutralizing antibody titers in specified subsets. These are immunogenicity measures, not observed reductions in infections, hospitalization or mortality. No results or U.S. combination approval are established by registration. The record is not yet recruiting; November 9, 2026 start and December 28, 2027 completion dates are estimates, not guaranteed readout dates.

Sources: ClinicalTrials.gov · NCT07890454.

Source date: 2026-10-26. Recorded in this review: October 27, 2026.

Results first posted October 26: NCT06663436 randomized 200 nine-month-old infants among low/medium/high altSonflex1-2-3 vaccine doses or active control (50 per arm). The study actually ran November 2024–October 2025; this is a new disclosure of older trial data.

Day-29 S. sonnei IgG geometric means were 44.6 (95% CI 32.2–61.7), 66.4 (46.9–93.9), 59.5 (44.7–79.1) and 8.7 (7.0–10.8) ELISA units/mL respectively, in 48/44/48/48 evaluable participants. These are antibody measurements, not measured protection against clinical shigellosis. Concomitant vaccines and active controls differ and matter for tolerability interpretation.

Safety denominators remain 50 per arm: one serious event in the low-dose arm, none in the other three, and no deaths. These counts do not establish vaccine causation or exclude uncommon harms. There is no U.S. Shigella-vaccine approval from these results. No dependable next clinical-efficacy readout date was verified.

Sources: ClinicalTrials.gov · NCT06663436.

Coverage and remaining gaps: focused_partial. Actual Hibsago commercial launch/coverage, full worldwide antibiotic/phage/antiviral appraisal and independent AI-phage patient outcomes remain gaps. Regulatory workshop timing is separate from efficacy.

Informal-source coverage: October 24/21 Reddit AI-phage reposts trace to the already-recorded October 20 sponsor statement; no new patient outcome independently confirmed. An October 26 phage discussion points to a formal CF pilot but supplies no result. Earlier adibelivir administrative rumor remains unconfirmed; original audio coverage incomplete.

Full coverage record.

October 20 original company report. Radical Numerics says an AI-designed phage treatment was administered to one patient with an antibiotic-resistant infection under an authorized, physician-led compassionate-use pathway. The exact administration date and clinical course are undisclosed. The company claims a first-of-its-kind milestone; that priority claim is not independently established here.

This is outside a conventional efficacy trial, not a randomized result or product approval. Laboratory killing of a patient’s bacterial isolate does not establish clinical recovery. The company explicitly withholds patient outcomes; there are no disclosed adverse-event rates, comparator, recurrence follow-up or durable-cure evidence. The FDA authorization described in secondary coverage was not independently verified from an individual authorization letter.

Next: a clinical report with response, safety, co-treatments and follow-up; no release date announced. Do not translate a reported administration into proven benefit or routine U.S. availability.

Sources: radicalnumerics.ai · source page.

First posted October 19 — NCT07881809 (A5420). NIAID plans a 45-person, masked randomized Phase 2 study of ixazomib versus placebo in adults whose HIV is suppressed on antiretroviral therapy. Participants continue their ART. The primary assessments include treatment-related grade 3-or-higher events, treatment discontinuation and post-dose low-level HIV RNA; reservoir DNA is secondary.

The intended mechanism is to expose latent infection for further clearance, but increased detectable viral RNA or a smaller measured reservoir is not proof of cure, safe ART withdrawal or reduced transmission. No results or trial-specific harms rates are available; the HIV use remains investigational. Status is not yet recruiting. Start November 23, 2026, primary October 8, 2027, and final November 5, 2027 are registry estimates.

Sources: ClinicalTrials.gov · NCT07881809.

First posted October 20 — NCT07883928. GC Biopharma plans 1,806 adults aged 65 or older, randomized and masked to GC3114B or Efluelda. Both are described as inactivated split influenza vaccines. The primary assessment is day-28 hemagglutination-inhibition antibody response; adverse reactions are assessed early and serious events through six months.

This is Phase 2/3, not a completed pure Phase 3 clinical-efficacy trial. Immune-response noninferiority does not itself show fewer infections, hospitalizations or deaths. The study remains not yet recruiting, with October 2026 estimated start, March 2028 primary and August 2028 final completion. No U.S. approval or availability for GC3114B is established by this registration.

Sources: ClinicalTrials.gov · NCT07883928.

First posted October 21 — NCT07885891. A masked randomized Phase 3 trial plans 324 adults with hospital-acquired or ventilator-associated bacterial pneumonia. Cefepime–zidebactam is compared with ceftazidime–avibactam, adding colistin for baseline pathogens presumed or confirmed resistant to the comparator; both groups receive initial linezolid coverage. These are treatment strategies, not a simple drug-only head-to-head.

The primary endpoint is 14-day all-cause mortality in the modified intention-to-treat population, with unknown survival status counted as death. Clinical/microbiological cure and later mortality are secondary. There are no results or trial-specific safety rates. Its existing U.S. complicated-UTI indication is separate from this investigational pneumonia use.

Status: not yet recruiting; October 28, 2026 estimated start, December 31, 2027 primary/final completion. A completion estimate does not promise a public readout.

Sources: ClinicalTrials.gov · NCT07885891.

Coverage and remaining gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (376 records). October 23 extended discovery through October 21–23 (47 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal-source coverage: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. The October 19 Communicable episode discusses published antibiotic trials; its linked papers/complete audio were not fully appraised. No additional trial result was inferred from commentary. The adibelivir CTIS administrative-modification claim remains unverified and non-material.

Full coverage record.

Agenda updated October 9; checked October 16. EMA schedules its bacteriophage-therapy workshop for October 30, 2026, 09:00–18:00 Amsterdam time (CET), with online participation. The agenda covers the clinical evidence and potential European regulatory framework for phage treatment of resistant infections.

This is a policy/evidence discussion, not a drug approval, new randomized result or harmonized authorization to use every phage product. No change to U.S. availability is established. The event page has a conflicting CEST broadcast heading; its dated agenda explicitly says CET.

Sources: EMA · source page; EMA · PDF document.

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 355 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. New completion labels for VAX-31 and VYD2311 do not add results beyond earlier disclosures; future-antibiotic/phage worldwide coverage remains selective.

Informal-source coverage: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Original adibelivir Reddit post describes an October 9 non-substantial CTIS modification whose contents were unavailable. That routine, unverified administrative inference was not promoted to an efficacy or approval rumor.

Full coverage record.

First posted October 13, 2026. GSK’s NCT07872046 plans a randomized masked phase 3 study of 16,390 adults aged at least 50, with established coronary/peripheral/cerebrovascular disease or at least two cardiovascular risk factors, on standard care. Two recombinant-zoster-vaccine doses at day 1/month 2 are compared with placebo. Primary time to first three-point MACE comprises nonfatal myocardial infarction, nonfatal stroke or cardiovascular death, with follow-up up to month 74. The population therefore spans secondary prevention and high-risk primary prevention, not everyone with prior MI.

Status/limits/safety/U.S.: Not yet recruiting; no hazard ratio or adverse-event results. A vaccine’s established shingles indication does not establish approval or efficacy for CV prevention. This randomized outcomes trial is distinct from observational vaccine associations.

Timing: November 30, 2026 estimated start; November 25, 2032 estimated primary/final completion. These are registry estimates, not confirmed readout dates.

Sources: ClinicalTrials.gov · NCT07872046.

Published October 12, 2026; full report of an older completed trial. NCT05933525 randomized 63 healthy adults (safety set); 60 underwent ETEC H10407 challenge, 30 per arm. Once-daily oral bovine-antibody Travelan 1,200 mg for seven days produced moderate/severe diarrhea in 6/30 (20%) versus 10/30 (33.3%): reported protective efficacy 40%, 95% CI −82.2% to 82.1%, nonsignificant. The lower-than-planned placebo attack rate reduced power but does not establish efficacy. Secondary endpoints had no multiplicity adjustment.

Safety/limits: No deaths or serious adverse events; one possible pre-challenge drug reaction. Post-challenge 55 versus 109 events are event counts largely attributed to infection, not proportions harmed by treatment. Nine withdrew before six-month follow-up. Single-strain challenge is distinct from natural-exposure diarrhea; microbiome/inflammation markers are not clinical protection.

U.S./next: Marketed as a dietary supplement, not FDA-approved travelers’-diarrhea prevention. Larger confirmatory human studies and an investigational enteric formulation are undated. Earlier sponsor topline dates remain historical.

Sources: Nature · article; ClinicalTrials.gov · NCT05933525.

Historical baseline, recovered October 13, 2026. NCT06889701 began April 3, 2025 (actual) and now lists recruiting, 33 planned participants: three sentinel patients, twenty randomized open-label participants and ten in an expansion cohort. TNP-2092 50 mg intra-articularly is studied alongside background antibiotics; randomized controls receive local vancomycin plus systemic/background antibiotics. Primary adverse-event safety runs through day 187; cure and prosthesis preservation require separate comparative evidence.

Limits/safety/U.S.: No results posted. This is a formal investigational antibiotic program, not established treatment or proven resistance reversal. Existing co-treatment limits attribution. Next: January 2027 primary/final completion estimates, no promised publication date.

Sources: ClinicalTrials.gov · NCT06889701.

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 325 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved.

Informal-source coverage: Targeted antibiotics/phage/vaccine Reddit and interview searches returned older studies and routine treatment anecdotes. No specific attributable new development rumor selected; full podcast/talk transcripts not appraised.

Full coverage record.

First posted October 7, 2026. NCT07863401 plans 400 lung-transplant or allogeneic hematopoietic-stem-cell-transplant recipients in a randomized, open-label comparison of two RSV vaccination strategies. The record compares a single adjuvanted regimen with a two-dose nonadjuvanted recombinant prefusion-F regimen, with antibody-response assessment one month after completing vaccination in each transplant subcohort. The narrative and coded product names disagree, so exact product identity requires protocol clarification.

Limits/safety/U.S.: The narrative also refers to RSVpreF while intervention coding uses RSVpreF3; product identity needs protocol clarification, so no brand is assigned here. An antibody-rise endpoint is not measured protection from RSV hospitalization or death. No human outcomes or quantified harms are posted. This study does not create a new U.S. transplant-specific indication.

Next: Not yet recruiting; October 2026 start, June 2028 primary and May 2029 final completion are registry estimates at month precision. Public-result timing is unknown.

Primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (312 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; VAX-31 topline and earlier PLG0206/China RSV/TNP2092 events already saved and deduplicated. No actual STEPS-CF first dosing verified. Broader new-antibiotic human efficacy, regulator files, conference abstracts and long-acting infection-prevention census remain incomplete. Gepotidacin resistance paper has September 1 online date despite October issue; not relabeled new October news.

Informal-source coverage: Located Communicable E64 (October4, Emily McDonald/Marc Bonten with Sylvain Lother/Valentijn Schweitzer) and Children’s Colorado Charting Pediatrics October6 show notes. These discuss existing antibiotic evidence/ stewardship rather than a new-development claim; full audio unreviewed. Read original personalized-phage-guideline Reddit discussion; expert consensus is not randomized efficacy. No separate noteworthy new rumor selected.

Full coverage record.

Source date: October 5, 2026. Evidence: Sponsor topline and SEC-filed slides; OPUS-1 NCT07284654 randomized 4,047 adults, including 3,572 aged ≥50 and 475 aged 18–49.

At one month, all 28 shared-serotype primary noninferiority assessments and four unique/cross-reactive superiority assessments passed. Primary analysis allowed PCV20 and/or PCV21 comparators with multiplicity control. Individual PCV21 comparisons passed 17/19 at the >0.667 confidence-bound margin; serotypes 3 and 12F only met the historical >0.5 margin. Younger-to-older immune bridging passed all 32 assessments.

Safety: In adults ≥50, serious adverse events were 14/1,194 VAX-31, 13/1,195 PCV20 and 13/1,183 PCV21. Four deaths occurred (two VAX-31, two PCV21), all assessed unrelated; no vaccine-related serious events or AE discontinuations were reported.

Limits/U.S.: Six-month safety and antibody function do not directly measure pneumonia/mortality prevention or prove superiority in every comparison. Investigational, not approved.

Next: OPUS-2/3 and infant phase 2 data H1 2027; adult BLA H1 2028, sponsor forecasts.

Original sponsor release; SEC-filed trial slides; OPUS-1 registry.

Source date: October 5, 2026 first posting. Evidence: NCT07858916, phase 2b design (registry phase 2), not yet recruiting in China.

Forty planned adults with prosthetic-joint infection receive intra-articular TNP-2092 with background infection care. Two acute-infection groups randomize daily 14-day versus weekly four-week dosing, ten per arm; up to 20 chronic-infection patients form a separate cohort. Primary outcome is six-month treatment failure, including infection-related death or additional treatment.

Limits/safety/U.S.: Open-label, no placebo/usual-care-only comparator, and no posted results. This cannot establish superiority, safety or eradication of biofilm. U.S. approval/access for this investigational regimen is not established.

Next: October 2026 start, September 2027 primary and March 2028 final completion are estimated.

Primary registry.

Source date: October 6, 2026 first posting; registry-reported actual start August 21. Evidence: NCT07860216, recruiting phase 3 randomized masked trial in China.

The study plans 25,000 adults aged ≥60, comparing a recombinant RSV vaccine produced in CHO cells with saline placebo. Primary outcome is first RT-PCR-confirmed RSV lower-respiratory disease over the first surveillance season.

Limits/safety/U.S.: No clinical results, adverse-event rates or demonstrated efficacy. A protocol’s assumed vaccine efficacy is a sample-size assumption, not a trial result. Approval of other RSV products does not authorize this formulation; U.S. approval is not established here.

Next: Primary/final completion December 31, 2028 is estimated; public readout timing unknown.

Primary registry.

Source/event date: 2026-09-29. Evidence: Sponsor-only randomized phase 3 topline.

LIBERTY (NCT07655180) randomized 210 healthy adults aged 18–49 among VYD2311 250 mg, Comirnaty, or both. Six-day adverse events/injection reactions/hypersensitivity occurred in 56.5% with VYD2311 versus 91.4% with Comirnaty; systemic events occurred in 44.1% versus 68.1%. No VYD2311-related event exceeded grade 2; no arm reported hypersensitivity/anaphylaxis. This small, short comparison does not establish rare/long-term safety or prevention of COVID. The sponsor's 70–90% efficacy figure is a target, not an observed result. DECLARATION (NCT07298434) safety and neutralizing-titer data are forecast for October; clinical efficacy remains blinded, with unblinding dependent on events and a proposed conditional-approval path. Neither FDA approval nor a submitted application is established. VYD2311 remains investigational and is distinct from Pemgarda. Sponsor.

Next milestone: October 2026 — sponsor forecast for DECLARATION safety and neutralizing-titer topline; clinical efficacy remains blinded.

Sponsor; ClinicalTrials.gov · NCT07655180; ClinicalTrials.gov · NCT07298434.

Source/event date: 2026-09-24. Evidence: Institutional announcement of planned human research.

Fraunhofer and Leicester describe REPhRAME, a five-year European collaboration intended to test bacteriophages for recurrent urinary infections. A Frankfurt-led randomized clinical study is planned to compare phages alone, phages with antibiotics, and phages with gut-microbiota restoration. This is a credible human-stage research plan, not evidence of effectiveness. No trial ID, enrollment target, first dosing or result date was verified. It does not establish U.S. approval or availability. Fraunhofer, Leicester.

Next milestone: Trial protocol/registration and first participant dosing; dates unknown.

Fraunhofer; Leicester; sciencemediahub.eu · article.

Source date: 2026-09-17. Evidence: Sponsor-reported trial authorization; recovered overlap finding.

SASPiPhi reported MHRA authorization for a first-in-human phase 1b/2a engineered-phage study in cystic fibrosis with Pseudomonas lung infection. STEPS-CF/SASPject PT3.9 plans 44–64 participants at Liverpool and up to ten additional UK sites. Sponsor cites ISRCTN57413769.

Limitations: Authorization explicitly remains conditional on funding, insurance and final HRA authorization. Registry redirected to a holding page; design, recruitment and start date were not independently verified. The September 17 announcement is newly appraised, not a September 29 trial launch.

Safety: No clinical efficacy or safety outcomes yet.

U.S. status: No U.S. approval; UK trial authorization is not treatment availability.

Next milestone: Funding/insurance/HRA completion and actual first dosing; no dependable date announced.

SASPiPhi September 17 release; STEPS-CF registry; access unavailable.

Source date: 2026-09-09. Evidence: Recovered baseline: sponsor development update and registries. Baseline addition; not new news.

BV100, an intravenous rifabutin formulation, is in phase 3 combination testing for carbapenem-resistant Acinetobacter pneumonia. RIV-TARGET NCT07326540 is recruiting; actual start March 27, 2026. Randomized Part A compares BV100/low-dose polymyxin B with colistin/high-dose ampicillin-sulbactam; primary endpoint 28-day mortality. RIV-CARE NCT07431307 is a separate open-label randomized phase 2b combination study with a safety-primary endpoint.

Limitations: September sponsor target around 300 differs from older RIV-TARGET registry estimate 248. RIV-CARE’s February record remains not-yet-recruiting despite elapsed July estimate; sponsor September site-start/H2 first-patient forecasts do not verify initiation. No new efficacy result; prior small-study mortality claims not reappraised.

Safety: Combination antibacterial safety, including renal and neurologic toxicity, requires full trial data; no new comparative safety table reported.

U.S. status: Investigational; September 2 Fast Track designation is not approval.

Next milestone: Sponsor: RIV-TARGET DSMB by end-2026, topline early 2028; RIV-CARE first patient H2 2026 and interim H1 2027. Registry primary completion: December 30, 2027 and March 2028 respectively.

BioVersys September 9 update; RIV-TARGET registry; RIV-CARE registry; BioVersys Fast Track announcement.

Source date: 2026-09-16. Event date: 2026-09-16. Evidence: Peer-reviewed randomized noninferiority trial.

For selected surgically managed orthopedic infections with local antibiotic carriers, a short systemic course was noninferior to a longer course. 500 adults were randomized; 475 entered primary analysis. At 12 months, failure occurred in 26/234 (11.1%) assigned ≤7 days versus 34/241 (14.1%) assigned ≥4 weeks. Difference −3.0 percentage points (95% CI −9.0 to 3.0), against a 10-point noninferiority margin. Trial: NCT03806166.

Limitations: Open-label treatment with blinded endpoint adjudication. Do not extrapolate to infections without implanted local antibiotics or to all orthopedic/hardware infections. September 16 publication recovered in this overlap search, not a September 27 result.

Safety: Potential treatment-related symptoms at six weeks were 17.2% versus 45.2% (difference −28.0 points, 95% CI −36.4 to −19.6). Full serious-event tables not appraised.

U.S. status: Treatment-duration evidence, not a new antibiotic approval.

Next milestone: Clinical adoption and subgroup appraisal; no dated new readout announced.

Short or Long Antibiotic Regimens in Orthopaedics, PubMed; SOLARIO original NEJM article.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor-reported FDA filing action.

FDA accepted Insmed’s supplemental application for full approval and broader MAC lung-disease use, with a January 28, 2027 action target. The application relies on phase 3b ENCORE: 425 participants with a new occurrence of MAC infection received ARIKAYCE plus azithromycin/ethambutol or placebo plus the same antibiotics. Respiratory symptoms and culture conversion are separate outcomes. Existing results are not newly generated by filing acceptance.

Limitations: Priority review is not approval; the release does not supply full numerical endpoint or safety tables.

Safety: The established product carries respiratory-risk warnings, including hypersensitivity pneumonitis, hemoptysis, bronchospasm and exacerbation of underlying lung disease; the sponsor reports no new ENCORE signal.

U.S. status: Current accelerated approval remains limited to adults with refractory MAC, limited alternatives and persistent positive cultures after at least six months of multidrug treatment. Earlier-line use remains under review.

Next milestone: January 28, 2027: sponsor-reported FDA action target, not guaranteed approval.

Insmed September 21 release.

Source date: 2026-09-11. Evidence: Investigator enrollment report and trial registry.

WVU reported its first participant in RETAIN, a controlled trial of PLG0206 irrigation alongside surgery and antibiotics for infected knee replacements. NCT07214311 is a recruiting randomized placebo-controlled phase 2/3 study targeting 240 participants. It measures treatment failure through 12 months after debridement, antibiotics and implant retention, with surgery, survival and function also tracked. The registry lists a February 3, 2026 global start; September is a site-enrollment report, not global trial initiation.

Limitations: This newly added formal antimicrobial program addresses biofilm-associated infection, not cartilage regeneration. Laboratory activity and earlier small studies do not establish superiority, broad resistant-infection efficacy or implant retention benefit.

Safety: No new comparative efficacy or safety results were reported.

U.S. status: Investigational; Orphan/Fast Track/QIDP designations are not approval.

Next milestone: September 2028 primary completion is the September 18 registry estimate; public results timing is unknown.

WVU investigator update, September 11; RETAIN registry.